Translate
Arabic
Chinese (Simplified)
Dutch
English
French
German
Italian
Portuguese
Russian
SpanishCelltrion
Fast Facts
Location: Branchburg
Industry: Life Sciences
Country of origin: South Korea
Type of facility: Manufacturing plant (ful-cycle biologics manufaturing)
South Korean biopharmaceutical leader Celltrion Inc. announced the acquisition of a 37-acre manufacturing site in Branchburg, New Jersey, previously owned by Eli Lilly and Company, for approximately $330 million. The facility comprises four buildings and about 10 acres of vacant land reserved for future expansion.
The acquisition is a strategic move by Celltrion to fully mitigate the risk of U.S. import tariffs on biologics, enabling domestic production of its medicines in the U.S. market. The facility is expected to allow the company to achieve cost savings through reduced shipping and external contract-manufacturing costs, as well as by leveraging a turn-key operation with an existing workforce and infrastructure.
Celltrion intends to validate and begin operations at the facility within a 12- to 18-month timeframe, with the aim of starting production of both its biosimilar products and contract manufacturing for Lilly-originated products by late 2026. This move also underscores New Jersey’s strength in biomanufacturing talent, infrastructure, and ecosystem — offering Celltrion a foothold in a region with a robust life-sciences workforce and logistics advantages.
“With this U.S. plant acquisition, we have saved about 1.5 trillion won by eliminating tariff risks, avoiding the cost of building a new facility, securing production capacity, and retaining skilled talent.”
Seo Jung-jin
Chairman
Seo Jung-jin
Chairman